Payment overview · 2025
General Payments
$439.14
30 reported records · 11 companies
Healthcare provider profile · identity verified
Anthony Craig Carter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOMPKINSVILLE, KY · NPI 1104890276
Verified facts
What the public records show
CMS Open Payments records show Anthony Craig Carter, MD received $439.14 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Eliquis, Otezla, Qulipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.91 | 36.0% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $87.56 | 19.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.29 | 7.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.24 | 6.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.99 | 5.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.99 | 4.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.33 | 4.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.12 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.03 | 3.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.68 | 3.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 3.6% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.14 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $106.32 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $87.56 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.00 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 231 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 983 | 198 |
| Furosemide | Furosemide | 766 | 160 |
| Losartan Potassium | Losartan Potassium | 757 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 129 |
| Potassium Chloride | Potassium Chloride | 565 | 112 |
| Lisinopril | Lisinopril | 563 | 112 |
| Omeprazole | Omeprazole | 562 | 116 |
| Meloxicam | Meloxicam | 543 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 493 | 112 |
| Azithromycin | Azithromycin | 461 | 251 |
| Metformin Hcl | Metformin Hcl | 408 | 85 |
| Cefdinir | Cefdinir | 406 | 193 |
| Trazodone Hcl | Trazodone Hcl | 391 | 82 |
| Methylprednisolone | Methylprednisolone | 357 | 220 |
| Gabapentin | Gabapentin | 349 | 63 |
| Sertraline Hcl | Sertraline Hcl | 343 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 339 | 73 |
| Mirtazapine | Mirtazapine | 318 | 63 |
| Naproxen | Naproxen | 311 | 135 |
| Metoprolol Tartrate | Metoprolol Tartrate | 306 | 74 |
| Ropinirole Hcl | Ropinirole Hcl | 293 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 292 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 287 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 260 | 60 |
| Montelukast Sodium | Montelukast Sodium | 235 | 55 |
| Eliquis | Apixaban | 231 | 39 |
| Atenolol | Atenolol | 227 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 48 |
| Amitriptyline Hcl | Amitriptyline Hcl | 207 | 49 |
| Levofloxacin | Levofloxacin | 206 | 133 |
| Prednisone | Prednisone | 204 | 97 |
| Ondansetron Hcl | Ondansetron Hcl | 187 | 77 |
| Citalopram Hbr | Citalopram Hydrobromide | 186 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 39 |
| Levetiracetam | Levetiracetam | 173 | 23 |
| Xarelto | Rivaroxaban | 170 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 163 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 161 | 42 |
| Spironolactone | Spironolactone | 160 | 31 |
| Glipizide | Glipizide | 159 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 76 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 156 | 101 |
| Pregabalin | Pregabalin | 148 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 146 | 76 |
| Lamotrigine | Lamotrigine | 143 | 26 |
| Buspirone Hcl | Buspirone Hcl | 142 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 137 | 31 |
| Warfarin Sodium | Warfarin Sodium | 131 | 23 |
| Januvia | Sitagliptin Phosphate | 130 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 129 | 42 |
| Ibuprofen | Ibuprofen | 124 | 27 |
| Celecoxib | Celecoxib | 122 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 119 | 89 |
| Sucralfate | Sucralfate | 118 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 32 |
| Simvastatin | Simvastatin | 114 | 31 |
| Clindamycin Hcl | Clindamycin Hcl | 113 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 26 |
| Carvedilol | Carvedilol | 108 | 36 |
| Donepezil Hcl | Donepezil Hcl | 108 | 22 |
| Famotidine | Famotidine | 108 | 22 |
| Allopurinol | Allopurinol | 101 | 26 |
| Fluconazole | Fluconazole | 100 | 52 |
| Topiramate | Topiramate | 99 | 19 |
| Clonidine Hcl | Clonidine Hcl | 98 | 28 |
| Metronidazole | Metronidazole | 95 | 62 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 21 |
| Alprazolam | Alprazolam | 92 | 14 |
| Glipizide Er | Glipizide | 91 | 14 |
| Baclofen | Baclofen | 89 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 22 |
| Meclizine Hcl | Meclizine Hcl | 88 | 37 |
| Primidone | Primidone | 88 | 20 |
| Sulindac | Sulindac | 88 | 36 |
| Cephalexin | Cephalexin | 87 | 67 |
| Bupropion Xl | Bupropion Hcl | 85 | 18 |
| Olanzapine | Olanzapine | 85 | 15 |
| Megestrol Acetate | Megestrol Acetate | 84 | 25 |
| Ozempic | Semaglutide | 83 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | suppressed |
| Clonazepam | Clonazepam | 78 | 11 |
| Digoxin | Digoxin | 77 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 16 |
| Bumetanide | Bumetanide | 76 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 23 |
| Promethazine Hcl | Promethazine Hcl | 75 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 18 |
| Tramadol Hcl | Tramadol Hcl | 74 | 24 |
| Finasteride | Finasteride | 73 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 17 |
| Mupirocin | Mupirocin | 72 | 46 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 71 | 47 |
| Mounjaro | Tirzepatide | 69 | suppressed |
| Jardiance | Empagliflozin | 68 | 14 |
| Nystatin | Nystatin | 67 | 42 |
| Dexlansoprazole Dr | Dexlansoprazole | 65 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 64 | suppressed |
| Risperidone | Risperidone | 64 | 12 |
| Lorazepam | Lorazepam | 62 | 15 |
| Metolazone | Metolazone | 62 | 26 |
| Propranolol Hcl | Propranolol Hcl | 62 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 41 |
| Divalproex Sodium | Divalproex Sodium | 58 | 15 |
| Linzess | Linaclotide | 56 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Fenofibrate | Fenofibrate | 55 | suppressed |
| Ondansetron Odt | Ondansetron | 54 | 35 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Colchicine | Colchicine | 51 | 14 |
| Glimepiride | Glimepiride | 50 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 40 |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Vraylar | Cariprazine Hcl | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Ranolazine Er | Ranolazine | 48 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 47 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Methotrexate | Methotrexate Sodium | 43 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 19 |
| Cevimeline Hcl | Cevimeline Hcl | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 39 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 37 | 16 |
| Acyclovir | Acyclovir | 36 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 14 |
| Estradiol | Estradiol | 35 | suppressed |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 13 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 12 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 19 |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | 21 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 25 | 19 |
| Roflumilast | Roflumilast | 25 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 22 | 16 |
| Sulfasalazine | Sulfasalazine | 22 | 11 |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Otezla | Apremilast | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sure Comfort | Pen Needle, Diabetic | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 13 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 12 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Ethosuximide | Ethosuximide | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.14 · 30 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FANAPT, GVOKE HYPOPEN, HETLIOZ, Korlym, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SUBLOCADE, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error